CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 ( Zurich June 1 2007-Cytos Biotechnolo...)

HOME >> MEDICINE >> TECHNOLOGY

CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted to inform you about the upcoming scientific presentations of its novel immunotherapeutic CYT003-QbG10 to treat allergic diseases. Recently, positive clinical results for CYT003-QbG10 were obtained and will be presented in different sessions at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI), taking place from June 9-13, 2007 in Göteborg, Sweden. The EAACI Congress has developed into one of the most important annual events in the field of Allergy in the world. For more information please visit ww.congrex.com/eaaci2007.

CYT003-QbG10 presentations at EAACI 2007: 1) Oral presentation of Abstract No. 146: Dust mite allergy - new treatment options. Dr. med. Thomas Kündig, Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland will present the CYT003-QbG10 study findings relating to house dust mite allergy on Tuesday, June 12, 2007; Oral Abstract Session 26 - Novel developments in basic allergology; 3.30 - 5.00 pm (CET).

2) Poster presentation of Abstract No. 183: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy. Presentation is on Sunday, June 10, 2007; Poster Discussion Session 1 - Immunotherapy; 10.00 - 12.00 am (CET).

3) Poster presentation of Abstract No. 714: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy. Presentation is on Sunday, June 10, 2007; Poster Session - Allergen SIT IV; 12.00 -1.30 pm (CET).

Background: CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb f
'"/>

Page: 1 2
Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
5. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
6. Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema
7. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
8. Data to be presented at AAN Meeting -Study results of drug candidate for MS
9. Data supporting three Antisoma programmes presented at AACR
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:

( Zurich June 1 2007-Cytos Biotechnolo...)CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007,Health